Hristina performs high-throughput drug sensitivity screens in cancer cell lines and organoids, as well as synthetic lethal CRISPR-Cas9 screens, with the aim of elucidating cancer vulnerabilities, new drug combinations, and drug targets. She is passionate about translating cancer genomics research into better outcomes for patients.